Source comparison
TB-500 Versus BPC-157: Scar Healing Mechanism Comparison
Primary Mechanism Actin upregulation + VEGF-driven angiogenesis VEGF receptor activation + growth hormone pathway stimulation TB-500 works faster in acute wounds; BPC-157 stronger for chronic tissue repair Optimal Wound Phase Inflammatory + early proliferative
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Actin upregulation + VEGF-driven angiogenesis
- VEGF receptor activation + growth hormone pathway stimulation
- TB-500 works faster in acute wounds; BPC-157 stronger for chronic tissue repair
- Optimal Wound Phase
- Inflammatory + early proliferative (days 1–21)
- Proliferative + remodeling (days 7–90+)
- Combine both for full-phase coverage
- Half-Life
- ~2 hours (requires twice-weekly dosing)
- ~4 hours (daily dosing preferred)
- BPC-157 needs more frequent administration for steady plasma levels
- Evidence Base
- 40+ preclinical studies; 3 human case series
- 60+ preclinical studies; no published human RCTs
- Neither is FDA-approved; TB-500 has slightly more human data
- Injection Site
- Systemic (abdomen/thigh subcutaneous)
- Local or systemic. Can inject near injury site
- BPC-157's local injection offers targeted effect; TB-500 works systemically regardless
- Cost per 4-Week Protocol
- $180–$240 (loading phase)
- $120–$160 (daily dosing)
- BPC-157 cheaper per cycle but requires daily compliance
- The critical distinction: TB-500 excels at reducing scar formation in fresh wounds, while BPC-157 demonstrates superior efficacy in remodeling established scar tissue. A surgical incision benefits most from TB-500 started within 72 hours; a 6-month-old hypertrophic scar responds better to 8–12 weeks of BPC-157. We've observed optimal results when clinicians layer both peptides. TB-500 during the acute phase, transitioning to BPC-157 as the wound enters remodeling.